Researchers at the Institute for Bioengineering of Catalonia and West China Hospital introduced a bioactive nanoparticle therapy that restores blood-brain barrier function, enabling efficient clearance of amyloid-β peptides in Alzheimer's disease mouse models. This 'supramolecular drug' approach reduced brain plaques and facilitated cognitive recovery for up to six months, offering a promising neurovascular precision medicine paradigm distinct from conventional neuron-targeted nanomedicines.